ImmunityBio Inc. (NASDAQ:IBRX) went down by -2.53% from its latest closing price compared to the recent 1-year high of $45.42. The company’s stock price has collected 0.27% of gains in the last five trading sessions. Press Release reported 8 hours ago that CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
Is It Worth Investing in ImmunityBio Inc. (NASDAQ :IBRX) Right Now?
Plus, the 36-month beta value for IBRX is at 2.08. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for ImmunityBio Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $25.00. IBRX currently public float of 67.17M and currently shorts hold a 13.26% ratio of that float. Today, the average trading volume of IBRX was 1.29M shares.
IBRX’s Market Performance
IBRX stocks went up by 0.27% for the week, with a monthly drop of -23.04% and a quarterly performance of -37.59%, while its annual performance rate touched -14.65%. The volatility ratio for the week stands at 7.16% while the volatility levels for the past 30 days are set at 6.48% for ImmunityBio Inc.. The simple moving average for the period of the last 20 days is -7.29% for IBRX stocks with a simple moving average of -34.36% for the last 200 days.
IBRX Trading at -20.86% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.36% of loss for the given period.
Volatility was left at 6.48%, however, over the last 30 days, the volatility rate increased by 7.16%, as shares sank -21.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.56% lower at present.
During the last 5 trading sessions, IBRX rose by +0.27%, which changed the moving average for the period of 200-days by +31.03% in comparison to the 20-day moving average, which settled at $11.92. In addition, ImmunityBio Inc. saw -16.05% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at IBRX starting from Simon Barry J., who sale 88,787 shares at the price of $16.18 back on May 25. After this action, Simon Barry J. now owns 3,102,507 shares of ImmunityBio Inc., valued at $1,436,822 using the latest closing price.
Simon Barry J., the Director of ImmunityBio Inc., sale 21,223 shares at $16.02 during a trade that took place back on May 24, which means that Simon Barry J. is holding 3,191,294 shares at $340,071 based on the most recent closing price.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -82545.95 for the present operating margin
The net margin for ImmunityBio Inc. stands at -83227.93. The total capital return value is set at -67.96, while invested capital returns managed to touch -71.40.
Based on ImmunityBio Inc. (IBRX), the company’s capital structure generated 14.26 points at debt to equity in total, while total debt to capital is 12.48. Total debt to assets is 10.76, with long-term debt to equity ratio resting at 8.36. Finally, the long-term debt to capital ratio is 7.32.
When we switch over and look at the enterprise to sales, we see a ratio of 11,989.70, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 0.27 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.06.